Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Selank is a synthetic heptapeptide (7 amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in cooperation with the V.V. Zakusov Research Institute of Pharmacology. It is structurally derived from tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) naturally cleaved from the Fc region of immunoglobulin G, with a Pro-Gly-Pro tail added to the C-terminus to produce a dramatically different pharmacological profile.
Selank occupies a distinctive position among research peptides: it is approved in Russia for generalized anxiety disorder (GAD) and neurasthenia, making it one of the few peptide anxiolytics with actual clinical regulatory approval anywhere in the world. The standard formulation is an intranasal nasal spray rather than injection.
Selank's defining clinical feature is anxiolytic efficacy comparable to benzodiazepines without sedation, cognitive impairment, tolerance, or dependence. The mechanism is multi-target rather than single-receptor: GABAergic modulation, enkephalinase inhibition, BDNF upregulation, serotonin metabolism modulation, dopaminergic effects, and immune/cytokine regulation under stress conditions.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Intranasal Selank (Russian-approved nasal spray) | Cleared from circulation within ~10 minutes by sensitive detection; sustained biological effects via active fragments |
| Subcutaneous Selank (research use) | Similar rapid clearance |
What it does
Main effects
- Anxiolytic efficacy comparable to benzodiazepines: Zozulya et al. comparative trial vs medazepam (62 patients) demonstrated comparable efficacy with substantially fewer side effects; randomized placebo-controlled trial in GAD (N=60, 400 mcg intranasal three times daily for 14 days) significantly reduced Hamilton Anxiety Rating Scale (HAM-A) scores vs placebo
- Russian regulatory approval for generalized anxiety disorder (GAD) and neurasthenia, one of few peptide anxiolytics with actual clinical regulatory approval globally
- Anxiolysis without sedation, cognitive impairment, tolerance, dependence, or withdrawal reported across the Russian clinical literature
- Multi-target mechanism including GABAergic modulation (allosteric, different binding site than benzodiazepines), enkephalinase inhibition (stabilizing endogenous enkephalins), BDNF upregulation in hippocampus, serotonin and dopamine metabolism modulation, cytokine/IL-6 regulation under stress
- Cognitive enhancement (nootropic) properties alongside anxiolytic effects
- Antiviral properties inherited from tuftsin origin (separate effect)
- Sustained mood and stress benefits: BDNF effects support effects beyond acute anxiolysis
- Intranasal administration is standard (Russian-approved nasal spray), unusual among research peptides; direct CNS delivery via olfactory pathway
- ~20 years of Russian clinical use with generally favorable real-world experience
What to watch for
Common side effects
- Notably ABSENT side effects: no sedation, no cognitive impairment, no motor coordination effects, no anterograde amnesia, no physical dependence, no tolerance development, no withdrawal syndrome, no abuse potential, no respiratory depression. This absence is Selank's defining safety advantage
- Notably ABSENT antidepressant side effects: no sexual dysfunction, no weight gain, no activation syndrome, no documented suicidality concerns
- Notably ABSENT antipsychotic side effects: no movement disorders, no metabolic effects, no prolactin elevation
- Mild headache: occasional, generally self-limited
- Mild fatigue: uncommon
- Nasal irritation from intranasal administration: mild
- Mild dizziness: rare
- Vivid dreams: reported by some users
- Rare allergic reactions: possible with any peptide
- Pregnancy and lactation safety unestablished: conservative approach to avoid use
- Pediatric data limited
- Few drug interactions: no CYP-mediated metabolism; synergistic with diazepam in animal models; generally compatible with other psychotropic medications
- Russian approval doesn't translate to Western pharmaceutical standards: evidence base is meaningful but operates outside FDA regulatory framework
- Not currently WADA-prohibited (verify current status before use in tested sport)
- Quality concerns for research chemical Selank vs Russian-approved standardized nasal spray product
Key facts
Key facts worth knowing
- Selank is a synthetic heptapeptide with sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids). The first four amino acids (Thr-Lys-Pro-Arg) are identical to tuftsin, an endogenous tetrapeptide. The added Pro-Gly-Pro tail transforms the immunomodulatory tuftsin into a neuroactive anxiolytic with dramatically different properties.
- Approved in Russia for generalized anxiety disorder and neurasthenia. One of few peptide anxiolytics with actual clinical regulatory approval globally.
- Tuftsin origin matters: Tuftsin (Thr-Lys-Pro-Arg) was discovered in 1970 as a natural product of IgG cleavage that stimulates phagocytosis and activates macrophages and neutrophils. Selank retains tuftsin's immunomodulatory effects while adding anxiolytic and nootropic properties.
- Standard administration is intranasal nasal spray, the Russian-approved formulation. This is unusual among research peptides (most are subcutaneous injection).
- Multi-target mechanism including GABAergic modulation (allosteric modulation of GABA-A receptors), enkephalinase inhibition (stabilizing endogenous enkephalins, natural anxiolytic peptides), BDNF (brain-derived neurotrophic factor) upregulation in hippocampus, serotonin metabolism modulation, dopaminergic modulation, cytokine and IL-6 regulation under stress conditions, antiviral properties (separate effect).
- Clinical evidence is meaningful for a Russian-approved peptide: randomized double-blind placebo-controlled trial in GAD (N=60) showed intranasal Selank 400 mcg three times daily for 14 days significantly reduced HAM-A scores vs placebo; Zozulya et al. comparative trial vs medazepam (benzodiazepine) in 62 patients demonstrated comparable anxiolytic efficacy; foundational pharmacology papers (Seredenin 2008, Andreeva 2005, Shadrina 2020).
- Anxiolytic efficacy comparable to benzodiazepines but without sedation, cognitive impairment, physical dependence, tolerance development, or withdrawal syndrome. Rapid metabolism: cleared from circulation within 10 minutes by sensitive detection; generated fragments may retain biological activity.
- Generally considered to have a remarkably clean safety profile: no serious adverse effects documented in clinical trials, no abuse potential, no significant drug interactions. Companion compound: Semax, another Russian-developed neuropeptide with related pharmacology (ACTH 4-10 analog), also approved in Russia. WADA status: Not currently on the WADA Prohibited List (verify current status before use in tested sport).
Legal status
Legal status
Approved in Russia for generalized anxiety disorder and neurasthenia. Not FDA-approved in the United States. Available through unregulated sources and limited compounding (with evolving regulatory status). Not a controlled substance. Not currently WADA-prohibited (verify current status before use in tested sport).